Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Karim Boussebaa as Chief Executive Officer of the Group. Meeting today, Guerbet’s Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Mr. Karim Boussebaa as Chief Executive Officer. This appointment will take effect on ...

Board Composition Changes - Guerbet's Annual General Meeting voted to reduce the terms of office of directors from six years to four years to comply with the Afep-Medef Code of corporate governance [2][9] - The terms of office for Claire Jouault Massiot, Céline Lamort, Mark Fouquet, Didier Izabel, and Jean-Sebastien Raynaud expired at the Annual General Meeting, and Pascale Auger resigned as a director [3][11] - Two new directors were appointed, Michèle Lesieur and Eric Drapé, while Céline Lamort and Marc Massiot were re-elected, bringing the total number of directors to nine [3][10][11] New Appointments - Michèle Lesieur was appointed as an independent director for a three-year term, bringing extensive experience in the healthcare sector, including leadership roles at Philips and Supersonic Imagine [4][5] - Eric Drapé was appointed as an independent director for a four-year term, with over 35 years of experience in the pharmaceutical industry, including senior positions at Teva Pharmaceuticals and Ipsen Pharma [6][7] Board Structure - The current Board of Directors consists of nine members, including three independent directors: Hugues Lecat, Eric Drapé, and Michèle Lesieur [11][12] - The Board expressed gratitude to outgoing directors for their contributions and welcomed the new appointees [11] Company Overview - Guerbet is a leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a revenue of €841 million in 2024 [13] - The company invests 9% of its sales in research and development across four centers in France and the United States [13]